DCTHDelcath Systems, Inc.
$15.03+39% 1Y
$15.03
$8.1952 weeks$17.37
DCTH in its own filings
DCTH's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
649
Events found in the filings · across 1,642 filings · the record starts in 2000
- Hard flags
- 3
Hard flags
- Most recent filing
- Aug 14, 2026
Most recent filing · Form 8-K
- Record starts
- Dec 4, 2000
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
- Change in certifying accountant5 occurrences
- 2025-03-21
- Late periodic report3 occurrences
- 2023-05-12
- Delisting notice / listing-rule failure12 occurrences
- 2024-07-09
- Security removed from listing or deregistered5 occurrences · usually a matured note or preferred class, not the common shares
- 2017-12-07
- SEC comment-letter activity74 occurrences
- 2024-08-01
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 14, 2026Amended and Restated Bylaws On August 12, 2026, the Board of Directors (the “Board”) of Delcath Systems, Inc. (the “Company”), acting upon the recommendation of the Nominating and Corporate Governance Committee of the Board, amended and restated the Company’s Amended and Restated By-Laws (the “Bylaws”), effective …Charter/bylaw amendment or fiscal-year change · Form 8-K
- Aug 6, 2026Delcath Systems Reports Second Quarter 2026.Earnings release · press release
- May 14, 2026Omnibus Equity Incentive Plan At the 2026 annual meeting of stockholders held on May 13, 2026 (the “Annual Meeting”), the stockholders of Delcath Systems, Inc. (the “Company”) approved an amendment to the Company’s 2020 Omnibus Equity Incentive Plan (the “2020 EIP”) to increase by 1,800,000 the number of shares of the …Director or officer change · Form 8-K
- May 7, 2026Delcath Systems Reports First Quarter 2026.Earnings release · press release
- Mar 3, 2026CHOPIN Study On March 3, 2026, Delcath Systems, Inc. issued a press release announcing publication of CHOPIN clinical trial results in the Lancet Oncology.Other event · Form 8-K
- Feb 26, 2026Delcath Systems Reports Fourth Quarter and.Earnings release · press release
- Jan 12, 2026On January 9, 2026, Delcath disclosed in the Corporate Presentation that as of December 31, 2025, (i) it had a total of 25 active sites utilizing HEPZATO KIT and (ii) there were approximately 34.7 million shares of its common stock issued and outstanding.Earnings release · Form 8-K
- Nov 20, 2025On November 19, 2025, the board of directors of Delcath Systems, Inc., a Delaware corporation (the “Company”) authorized a share repurchase program under which the Company may repurchase up to $25 million of its outstanding shares of common stock from time to time, subject to market conditions.Other event · Form 8-K
- Nov 4, 2025Delcath Systems Reports Third Quarter 2025.Earnings release · press release
- Oct 20, 2025CHOPIN Trial On October 18, 2025, Delcath issued a press release announcing the results of the CHOPIN Trial.Earnings release · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…